Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca

GlaxoSmithKline

Johnson & Johnson

Merck

Novo Nordisk

Novartis

Pfizer

Roche Holding AG

Sanofi

In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.

Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings

Rhythm Pharmaceuticals

A year ago, medical experts and Nobel Laureates interviewed by The New York Times proclaimed "a Golden Age of Medicine" is here.

Three Biotech Stocks to Buy for the "Golden Age of Medicine"

Novo Nordisk and Eli Lilly won't be constrained by manufacturing too much longer. That means they'll sell more of their in-demand drugs.

Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond

Alphabet

Banking giant Goldman Sachs (NYSE: GS) has identified several stocks likely to witness an upside in the future based on their key fundamentals.

2 Goldman Sach stocks to turn $100 to $1000 by 2025

Last November, Eli Lilly received FDA approval for obesity drug Zepbound. In the second quarter, Zepbound generated over $1.2 billion in revenue!

Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived

Eli Lilly is one of a few corporations close to hitting the $1 trillion mark. Despite a rich-looking valuation, the company should continue delivering strong returns.

Prediction: This Hypergrowth Company Could Be the Next Trillion-Dollar Stock

Broadcom

Bank of America

Carlisle Companies

Cintas Corp

Dick's Sporting Goods

Comfort Systems USA

NRG Energy

NetApp

PulteGroup

This article focuses on selecting high-growth dividend stocks with rapidly growing dividends rather than high current yields. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The article provides criteria for selecting high-growth dividend stocks. It offers a step-by-step guide on structuring a portfolio based on this strategy.

Our Top 10 Dividend Growth Stocks - August 2024

The anti-obesity market is a huge growth opportunity in healthcare. Novo Nordisk and Eli Lilly dominate it today, but it may not be long before there's more competition.

Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years

Vertex Pharmaceuticals

Eli Lilly is a biopharma giant that could still deliver strong growth. Novo Nordisk's growth story isn't over thanks to Ozempic, Wegovy, and a promising pipeline.

3 Fantastic Growth Stocks to Buy in August

Eli Lilly's sales grew by 36% last quarter, largely due to the success of two products. The company has a promising molecule, tirzepatide, which has shown that it can help people lose significant weight.

Eli Lilly's Top GLP-1 Drugs Now Account for Nearly 40% of Its Revenue, and That's Likely to Go Higher in Future Quarters

INDIANAPOLIS , Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Marschall S. Runge, M.D.

Lilly announces retirement of Marschall S. Runge from its Board of Directors

Lilly (LLY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Lilly (LLY) Might be Well Poised for a Surge

Cardinal Health

Walmart

The 2024 Q2 earnings season is slowly grinding to a halt, with the vast majority of S&P 500 companies already delivering quarterly results. Peeking a bit ahead, earnings for the current period (2024 Q3) are expected to be up 4.3% on 4.6% higher revenues, chaining together consecutive periods of positivity.

3 Companies Reporting Remarkable Results: WMT, LLY, CAH

Morphic Holding Inc

Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS , Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).

Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Eli Lilly (LLY) a Strong Momentum Stock: Buy Now?

Is Eli Lilly stock a buy or a sell after diabetes and obesity treatments easily beat second-quarter sales expectations?

Is Eli Lilly Stock A Buy Or A Sell After Mounjaro And Zepbound Crush Expectations?

With the current market volatility, knowing which biotech stocks to buy on the dip can lead to lucrative returns as the industry is likely to recover faster than the market average. After all, many of the most prominent biomedical developers see their stock price rise or fall based on their drug success.

3 Biotech Stocks to Buy on the Dip: August 2024

Eli Lilly may be starting to gain an edge over Novo Nordisk in the GLP-1 market. Meanwhile, Stryker will acquire artificial intelligence startup Care.ai.

Healthy Returns: Eli Lilly gains momentum against Novo Nordisk in the weight loss drug market

Glp-1 drugs are predicted to become the top-selling pharmaceutical class ever, with projected US sales of $150 billion by 2030. I have written multiple articles on Glp-1 drugs, highlighting their potential impact on the pharmaceutical industry. These drugs are expected to revolutionize the market and generate significant revenue in the coming years.

Incretin Drug Class: Eli Lilly Likely A Big Beneficiary, As Are Many Other Companies

Eli Lilly has sent cease-and-desist letters to US healthcare providers in recent days demanding they stop promoting copycat weight-loss drugs as the supply of the company's drug Zepbound improves, Bloomberg News reported on Wednesday.

Lilly demands doctors stop selling copycat weight-loss drugs, Bloomberg reports

Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.

Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?

The market reacted very positively to Eli Lilly's Q2 earnings report. This isn't the first time the stock has seen a significant run-up in a short period.

Up 10% in 1 Day, Is It Too Late to Buy Eli Lilly Stock?

Biogen

Treating aging and its consequences will be a colossal market. The first seeds of the coming boom have already been planted.

Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs

Lilly (LLY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Lilly (LLY) Upgraded to Buy: Here's Why

AbbVie

Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales and earnings guidance for 2024.

News for Eli Lilly Stock (LLY)